Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement

NCT02644616 is registered in ClinicalTrials.gov with Shanghai Chest Hospital as lead sponsor.

NCT NCT02644616
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02644616 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement
Lead sponsor
Shanghai Chest Hospital
Phase
Phase 4
Overall status
Completed
Start date
November 30, 2014
Completion date
December 31, 2016
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

right heart failure, tricuspid regurgitation